NO943967D0 - Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider - Google Patents

Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider

Info

Publication number
NO943967D0
NO943967D0 NO943967A NO943967A NO943967D0 NO 943967 D0 NO943967 D0 NO 943967D0 NO 943967 A NO943967 A NO 943967A NO 943967 A NO943967 A NO 943967A NO 943967 D0 NO943967 D0 NO 943967D0
Authority
NO
Norway
Prior art keywords
mammal
nonself
suppression
tolerance
induction
Prior art date
Application number
NO943967A
Other languages
English (en)
Other versions
NO943967L (no
Inventor
Howard L Weiner
David A Hafler
Charles B Carpenter
Mohamed Sayegh
Zhengi Zhang
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of NO943967D0 publication Critical patent/NO943967D0/no
Publication of NO943967L publication Critical patent/NO943967L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
NO943967A 1992-04-20 1994-10-19 Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider NO943967L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87128992A 1992-04-20 1992-04-20
US96177992A 1992-10-15 1992-10-15
US97773792A 1992-11-13 1992-11-13
US08/027,127 US5593698A (en) 1990-10-31 1993-03-05 Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
PCT/US1993/003708 WO1993020842A1 (en) 1992-04-20 1993-04-20 Suppression of proliferative response and induction of tolerance with polymorphic class ii mhc allopeptides

Publications (2)

Publication Number Publication Date
NO943967D0 true NO943967D0 (no) 1994-10-19
NO943967L NO943967L (no) 1994-10-19

Family

ID=27487557

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943967A NO943967L (no) 1992-04-20 1994-10-19 Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider

Country Status (13)

Country Link
US (1) US5593698A (no)
EP (1) EP0637249B1 (no)
JP (1) JPH07505892A (no)
KR (1) KR100275656B1 (no)
AT (1) ATE205400T1 (no)
AU (1) AU686101B2 (no)
BR (1) BR9306345A (no)
CA (1) CA2118502A1 (no)
DE (1) DE69330752D1 (no)
HU (1) HUT71310A (no)
IL (1) IL105472A (no)
NO (1) NO943967L (no)
WO (1) WO1993020842A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US6156306A (en) * 1994-08-17 2000-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pancreatic β-cells for allogeneic transplantation without immunosuppression
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
CA2402489C (en) * 2000-03-15 2011-11-01 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
US7348005B2 (en) * 2000-03-15 2008-03-25 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
ES2292594T3 (es) 2000-05-24 2008-03-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services E-selectina para tratar o prevenir accidentes cerebrovasculares.
DK1311542T3 (da) * 2000-08-21 2008-11-10 Apitope Technology Bristol Ltd Tolerogene peptider
US7582313B2 (en) * 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US20040229785A1 (en) * 2002-11-15 2004-11-18 Denise Faustman Screening methods to identify treatments for autoimmune disease
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
WO2009022154A2 (en) 2007-08-15 2009-02-19 Circassia Limited Peptide with multiple epitopes
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
US10137181B2 (en) * 2014-04-01 2018-11-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated donor MHC-derived peptide and uses thereof
WO2016187068A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
KR102410778B1 (ko) 2016-05-13 2022-06-21 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364762A (en) * 1990-03-21 1994-11-15 Board Of Trustees Of The Leland Stanford Junior University Major histocompatibility complex (MHC) molecules

Also Published As

Publication number Publication date
AU4108393A (en) 1993-11-18
KR100275656B1 (ko) 2000-12-15
JPH07505892A (ja) 1995-06-29
ATE205400T1 (de) 2001-09-15
IL105472A (en) 1999-06-20
AU686101B2 (en) 1998-02-05
DE69330752D1 (de) 2001-10-18
KR950701228A (ko) 1995-03-23
EP0637249A4 (en) 1997-01-08
CA2118502A1 (en) 1993-10-28
HU9403006D0 (en) 1994-12-28
NO943967L (no) 1994-10-19
IL105472A0 (en) 1993-08-18
EP0637249A1 (en) 1995-02-08
US5593698A (en) 1997-01-14
HUT71310A (en) 1995-11-28
BR9306345A (pt) 1998-06-30
WO1993020842A1 (en) 1993-10-28
EP0637249B1 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
NO943967D0 (no) Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider
Raff et al. Mouse specific bone marrow-derived lymphocyte antigen as a marker for thymus-independent lymphocytes
PT735893E (pt) Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária
Pape et al. Characterization of Cytolytic Effector Cells in Peripheral Blood of Healthy Individuals and Cancer Patients: II. Cytotoxicity to Allogeneic or Autochthonous Tumor Cells in Tissue Culture
GR3034964T3 (en) Lymphocyte activity regulation by hla peptides.
WO1999003976A3 (en) Method of treating leukocytes, leukocyte compositions and methods of use thereof
IL99864A (en) Compositions for suppressing transplant rejection in mammals which contain tissue donor derived MHC antigens
ES2087163T3 (es) Preparacion antitumoral que comprende intreleucina-2 e histamina, analogo al de las mismas o agonistas de receptor h2.
Golstein et al. Mouse T cell-mediated cytolysis specifically triggered by cytophilic xenogeneic serum determinants: A caveat for the interpretation of experiments done under “syngeneic” conditions
EP0753005A4 (en) REGULATION OF CYTOTOXIC T LYMPHOCYTE ACTIVITY BY CLASS I MHC PEPTIDES
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
HK1011503A1 (en) Immunosuppressive compositions
Chan et al. Human anti‐pig cell‐mediated cytotoxicity in vitro involves non‐T as well as T cell components
Yang et al. The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD
AR002005A1 (es) Fragmentos de anticuerpos monoclonales que tienen actividad inmuno supresora, procedimiento para su preparacion, composicion farmaceutica que loscontiene y metodo para la supresion de la respuesta inmune.
NZ216519A (en) Polycyclic compounds and pharmaceutical compositions
Yamagishi et al. Specific and non‐specific immunologic mechanisms of tumor growth facilitation
Santoni et al. Secondary cytotoxic response in vitro against Moloney lymphoma cells antigenically altered by drug treatment in vivo
Fahey et al. Immunity to Plasmodium yoelii: kinetics of the generation of T and B lymphocytes that passively transfer protective immunity against virulent challenge
Paranjpe et al. Discussion paper: specific paralysis of the antitumor cellular immune response produced by growing tumors studied with a radioisotope footpad assay
Schmitz et al. Induction of long‐term graft acceptance by a combination treatment of donor splenocytes and CTLA4Ig in a high responder rat liver transplantation model
Chen et al. Splenic immune effector and suppressor cells in mice bearing a growing plasmacytoma
Tsokos et al. Concanavalin-induced suppressor cells: characterization on the basis of corticosteroid and radiation sensitivity.
Röllinghoff et al. Induction of secondary cytotoxic T-lymphocytes in vitro does not require cell proliferation
MY131097A (en) Pharmaceutical compositions comprising interleukin-2

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application